General
Preferred name
idarubicin
Synonyms
Idamycin ()
4-demethoxydaunorubicin (NSC256439, 4-DMDR) HCl ()
4-Demethoxydaunorubicin hydrochloride ()
Idarubicin HCl ()
Zavedos ()
IDARUBICIN HYDROCHLORIDE ()
Idarubicin (hydrochloride) ()
4-Demethoxydaunorubicin ()
Idarubicin (hydrochloride) ()
IMI 30 ()
Idarubicin Hydrochloride Pfs ()
Idamycin Pfs ()
IMI-30 ()
NSC-256439 ()
Idarubicina ()
Idarubicine ()
P&D ID
PD002710
CAS
57852-57-0
58957-92-9
Tags
available
drug
natural product
Approved by
FDA
First approval
1990
Drug indication
Acute myeloid leukaemia
Hepatocellular carcinoma
Acute myeloid leukemia
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.
PRICE 99
DESCRIPTION Idarubicin is an anthracycline type antineoplastic drug. (GtoPdb)
DESCRIPTION Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL. (BOC Sciences Bioactive Compounds)
DESCRIPTION Idarubicin hydrochloride (Zavedos), a hydrochloride salt form of Idarubicin, is a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells ( IC50: 3.3 ng/mL). (TargetMol Bioactive Compound Library)
DESCRIPTION Antineoplastic (LOPAC library)
Cell lines
8
Organisms
5
Compound Sets
23
AdooQ Bioactive Compound Library
A10465
BOC Sciences Bioactive Compounds
idarubicin-hydrochloride-cas-57852-57-0-item-84-94874
Cayman Chemical Bioactives
14176
ChEMBL Approved Drugs
CHEMBL1200976
CHEMBL1117
ChEMBL Drugs
CHEMBL1200976
CHEMBL1117
Drug Repurposing Hub
DrugBank
DB01177
DrugBank Approved Drugs
DB01177
DrugCentral
1414
DrugCentral Approved Drugs
1414
DrugMAP
DMM0XGL
DrugMAP Approved Drugs
DMM0XGL
EU-OPENSCREEN Bioactive Compound Library
EOS101383
Guide to Pharmacology
7083
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1117
MedChem Express Bioactive Compound Library
HY-17381
HY-17381A
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ZRP63D75JW
NIH Clinical Collections (NCC)
ReFrame library
Selleckchem Bioactive Compound Library
Idarubicin
TargetMol Bioactive Compound Library
T6010
External IDs
66
Properties
(calculated by RDKit )
Molecular Weight
497.17
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
5
Rotatable Bonds
3
Ring Count
5
Aromatic Ring Count
2
cLogP
1.02
TPSA
176.61
Fraction CSP3
0.42
Chiral centers
6.0
Largest ring
6.0
QED
0.33
Structural alerts
1
quinone_A(370)
[!#6&!#1]=[#6]1[#6]=,:[#6][#6](=[!#6&!#1])[#6]=,:[#6]1
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
DNA Damage/DNA Repair
Microbiology/virology
Anti-infection
Apoptosis
Cell Cycle/DNA Damage
Indication
acute myeloid leukemia (AML)
Target
TOP2A
antibiotic
Bacterial
c-Myc
DNA/RNA Synthesis
Fungal
Topoisomerase
Topo II (MCF-7 cells)
MOA
Topoisomerase inhibitor
Biosynthetic Origin
Polyketide (Aromatic), Carbohydrate (Aminoglycoside)
Therapeutic Indication
Anticancer
Therapeutic Class
Anticancer Agents
Solubility
Soluble in DMSO (Slightly), Methanol (Slightly)
Source data